Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.

AEON Biopharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 FDA TYPE 2A MEETING SCHEDULED FOR NOVEMBER 19, 2025, TO REVIEW AEON'S ANALYTICAL DEVELOPMENT PLAN AND INITIAL DATA   POSITIVE BIOSIMILARITY DATA FOR ABP-450 CONFIRMING IDENTICAL AMINO-ACID SEQUENCING AND HIGHLY SIMILAR FUNCTIONAL CHARACTERISTICS SUBMITTED TO FDA AHEAD OF SCHEDULED TYPE 2A MEETING   TWO COMPLEMENTARY FINANCING TRANSACTIONS ANNOUNCED IN NOVEMBER 2025 - $6 MILLION PIPE FINANCING AND A PROPOSED DAEWOONG NOTE EXCHANGE - ARE EXPECTED TO STRENGTHEN AEON'S BALANCE SHEET, REDUCE OUTSTANDING DEBT BY MORE THAN 90%, ACCELERATE THE ABP-450 BIOSIMILAR PROGRAM BY UP TO SIX MONTHS, AND EXTEND CASH RUNWAY INTO THE SECOND QUARTER OF 2026  IRVINE, CALIF., NOV. 14, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE AMERICAN: AEON), A BIOPHARMACEUTICAL COMPANY SEEKING AN ACCELERATED AND FULL-LABEL U.S. MARKET ENTRY BY DEVELOPING ABP-450 (PRABOTULINUMTOXINA) AS A BOTOX (ONABOTULINUMTOXINA) BIOSIMILAR, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A BUSINESS UPDATE.

AEON BIOPHARMA REPORTS THIRD QUARTER 2025 RESULTS, INCLUDING POSITIVE ABP-450 BIOSIMILARITY DATA AND STRATEGIC POSITIONING FOR CONTINUED GROWTH

-COMBINED TRANSACTIONS WILL STRENGTHEN BALANCE SHEET AND REDUCE OUTSTANDING DEBT BY MORE THAN 90% - - $6 MILLION PIPE FINANCING WITH POTENTIAL FOR OVER $7 MILLION OF ADDITIONAL CAPITAL VIA CASH-EXERCISE WARRANTS - - DAEWOONG HAS ENTERED BINDING TERM SHEET FOR EXCHANGE OF $15 MILLION OF NOTES PLUS ACCRUED INTEREST INTO EQUITY, $1.5 MILLION NEW NOTE DUE 2030 AND 8 MILLION CASH-EXERCISE WARRANTS TOTALING OVER $8M OF POTENTIAL PROCEEDS - - TRANSACTIONS EXPECTED TO SUPPORT UNINTERRUPTED ADVANCEMENT OF AEON'S ABP-450 BIOSIMILAR PROGRAM FOLLOWING POSITIVE ANALYTICAL DATA SUBMITTED TO FDA  IRVINE, CALIF., NOV. 13, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE AMERICAN: AEON), A BIOPHARMACEUTICAL COMPANY SEEKING ACCELERATED AND FULL-LABEL U.S. MARKET ENTRY BY DEVELOPING ABP-450 (PRABOTULINUMTOXINA) AS A BOTOX (ONABOTULINUMTOXINA) BIOSIMILAR, TODAY ANNOUNCED TWO COMPLEMENTARY TRANSACTIONS TOTALING UP TO ~$22 MILLION IN POTENTIAL PROCEEDS THAT WILL COLLECTIVELY TRANSFORM THE COMPANY'S BALANCE SHEET, ELIMINATE NEARLY ALL OUTSTANDING DEBT, AND PROVIDE CAPITAL TO ACCELERATE PROGRAM EXECUTION AHEAD OF AEON'S UPCOMING FDA TYPE 2A MEETING.

AEON BIOPHARMA ANNOUNCES FUNDRAISE TOTALING UP TO ~$22 MILLION THROUGH PRIVATE PLACEMENT AND PROPOSED EXCHANGE OF DAEWOONG CONVERTIBLE NOTES

- MEETING DATE ALIGNS WITH PRIOR GUIDANCE - - FDA TO REVIEW AEON'S ANALYTICAL DEVELOPMENT PLAN AND INITIAL DATA - IRVINE, CALIF., OCT. 01, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE: AEON), A BIOPHARMACEUTICAL COMPANY DEVELOPING ABP-450 (PRABOTULINUMTOXINA) AS A BOTOX (ONABOTULINUMTOXINA) BIOSIMILAR, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS SCHEDULED A BIOSIMILAR BIOLOGICAL PRODUCT DEVELOPMENT (BPD) TYPE 2A MEETING FOR ABP-450 ON NOVEMBER 19, 2025, IN LINE WITH PRIOR GUIDANCE.

AEON Biopharma, Inc.

AEON

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AEON Biopharma, Inc.

AEON.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AEON